Melexis Q3 2026 results – Third quarter sales of 223.7 million EUR

Press release - Regulated Information

Intermediate declaration by the Board of Directors
Ieper, Belgium – October 28th, 2026, 07.00 hrs CET

Melexis Q3 2026 results – Third quarter sales of 223.7 million EUR

Sales for the third quarter of 2026 were 223.7 million EUR, an increase of 4% compared to the same quarter of the previous year and an increase of 3% compared to the previous quarter. The EUR/USD exchange rate evolution had a positive impact of 1% on sales compared to the same quarter of last year and no impact on sales compared to the previous quarter.

The gross result was 91.1 million EUR or 40.7% of sales, an increase of 9% compared to the same quarter of last year and an increase of 4% compared to the previous quarter.

R&D expenses were 13.6% of sales, G&A was at 6.5% of sales and Selling was at 2.2% of sales.

The operating result was 41.3 million EUR or 18.5% of sales, an increase of 9% compared to the same quarter of last year and an increase of 7% compared to the previous quarter.

The net result was 31.3 million EUR or 0.78 EUR per share, an increase of 14% compared to 27.5 million EUR or 0.68 EUR per share in the third quarter of 2025 and an increase of 2% compared to the previous quarter.

Melexis Q3 2026 results – Third quarter sales of 223.7 million EUR

Sales for the first nine months of 2026 were 642.9 million EUR, an increase of 3% compared to the first nine months of 2025. The EUR/USD exchange rate evolution had a negative impact of 1% on sales compared to the first nine months of 2025.

The gross result was 259.6 million EUR or 40.4% of sales, an increase of 7% compared to the same period last year. R&D expenses were 13.9% of sales, G&A was at 6.7% of sales and Selling was at 2.2% of sales.

The operating result was 113.0 million EUR or 17.6% of sales, an increase of 10% compared to 102.5 million EUR in the same nine months of 2025.

The net result was 85.2 million EUR or 2.11 EUR per share, a decrease of 5% compared to 89.9 million EUR or 2.23 EUR per share in the first nine months of 2025.

Outlook

Melexis confirms its second half 2026 outlook, which is for sales to be between 445 and 455 million EUR, with a gross profit margin around 41% and an operating margin around 18%, all taking into account a EUR/USD exchange rate of 1.12 for the remainder of the year.

For the full year 2026, Melexis expects CAPEX to be around 40 million EUR.

Quote from CEO Marc Biron

"Our results in the third quarter of 2026 were in line with expectations. Now that customers have normalized their inventories, automotive demand is clearly growing driven by greater content, and we are gaining new business in targeted applications. Thanks to disciplined cost management, gross margins are up 170 basis points year-on-year in the first nine months.

We made further progress with our strategy to win in high-growth markets. In China, we signed a Master Purchase Agreement with BYD, a leading OEM. We also announced a new current sensor, our first integrated circuit (IC) produced through a localized manufacturing model in China, demonstrating our commitment to match customers' requirements. Our Q3 sales in China were the highest ever, with Q4 2026 orders pointing to a further increase. In India, we opened a new office in Pune, to build our local team and accelerate sales growth.

Our robotics technology is now powering active customer production earlier than expected. Q3 marks a milestone quarter where design wins have successfully translated into volume ramps, cementing our position as a leading solution supplier of physical AI.

Q3 demonstrates that our strategic choices are delivering tangible results. While maintaining cost discipline, we continue to drive a high rate of product releases to capture new business in our chosen growth areas."

Financial Calendar

  • Publication FY 2026 Results: February 3, 2027 (at 7 hrs CET)
  • Publication Q1 2027 Results: April 28, 2027 (at 7 hrs CET)
  • Publication Q2 2027 Results: July 28, 2027 (at 7 hrs CET)
  • Publication Q3 2027 Results: October 27, 2027 (at 7 hrs CET)
  • Publication FY 2027 Results: February 2, 2028 (at 7 hrs CET)

The company’s results will be discussed in English in an audio webcast and conference call on Wednesday, October 28th, 2026 at 10:30 hrs CET. Joining this event requires registration in advance.

To register for the audio webcast (no possibility to ask questions)

You can register for the audio webcast by clicking here.

To register for the conference call (possibility to ask questions)

You can register by clicking here and filling out the requested information. After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes, all participants must register individually if they wish to join the call.

For more information:
Investors
Investor Relations
Email: investor@melexis.com

Journalists
Brand & Communications
Email: brandcomms@melexis.com

Download press release (PDF - 221 kB)